share_log

Inari Medical Analyst Ratings

Benzinga Analyst Ratings ·  Sep 16, 2022 07:57
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/16/2022 27.46% Canaccord Genuity $92 → $94 Maintains Buy
09/13/2022 17.97% Truist Securities → $87 Initiates Coverage On → Hold
07/15/2022 26.1% Morgan Stanley $108 → $93 Maintains Overweight
06/24/2022 35.59% BTIG $130 → $100 Maintains Buy
06/21/2022 35.59% Piper Sandler → $100 Initiates Coverage On → Overweight
03/14/2022 30.17% Canaccord Genuity $102 → $96 Maintains Buy
02/24/2022 46.44% Morgan Stanley $119 → $108 Maintains Overweight
02/24/2022 28.81% SVB Leerink $85 → $95 Maintains Outperform
11/10/2021 62.71% SVB Leerink $110 → $120 Maintains Outperform
08/11/2021 49.15% SVB Leerink $126 → $110 Maintains Outperform
05/12/2021 78.98% Canaccord Genuity $129 → $132 Maintains Buy
05/12/2021 74.92% Morgan Stanley $126 → $129 Maintains Overweight
03/10/2021 69.49% Wells Fargo $112 → $125 Maintains Overweight
03/10/2021 74.92% Canaccord Genuity $94 → $129 Reiterates → Buy
03/10/2021 70.85% Morgan Stanley $85 → $126 Maintains Overweight
03/10/2021 70.85% SVB Leerink $116 → $126 Maintains Outperform
12/15/2020 7.12% Wells Fargo → $79 Upgrades Equal-Weight → Overweight
11/18/2020 24.75% BTIG → $92 Initiates Coverage On → Buy
11/13/2020 15.25% Morgan Stanley $76 → $85 Maintains Overweight
11/13/2020 22.03% SVB Leerink $80 → $90 Maintains Outperform
09/28/2020 8.47% SVB Leerink → $80 Initiates Coverage On → Outperform
08/12/2020 -10.51% Morgan Stanley $52 → $66 Maintains Equal-Weight
06/22/2020 -18.64% Canaccord Genuity → $60 Initiates Coverage On → Buy
06/19/2020 -18.64% Canaccord Genuity → $60 Initiates Coverage On → Buy
06/16/2020 -33.56% Wells Fargo → $49 Initiates Coverage On → Equal-Weight
06/16/2020 -29.49% Morgan Stanley → $52 Initiates Coverage On → Equal-Weight

Inari Medical Questions & Answers

What is the target price for Inari Medical (NARI)?

The latest price target for Inari Medical (NASDAQ: NARI) was reported by Canaccord Genuity on September 16, 2022. The analyst firm set a price target for $94.00 expecting NARI to rise to within 12 months (a possible 27.46% upside). 9 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Inari Medical (NARI)?

The latest analyst rating for Inari Medical (NASDAQ: NARI) was provided by Canaccord Genuity, and Inari Medical maintained their buy rating.

When is the next analyst rating going to be posted or updated for Inari Medical (NARI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inari Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inari Medical was filed on September 16, 2022 so you should expect the next rating to be made available sometime around September 16, 2023.

Is the Analyst Rating Inari Medical (NARI) correct?

While ratings are subjective and will change, the latest Inari Medical (NARI) rating was a maintained with a price target of $92.00 to $94.00. The current price Inari Medical (NARI) is trading at is $73.75, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment